IGIV in neurology - Evidence and recommendations

Canadian Journal of Neurological Sciences

Volumn 26, Issue 2, 1999, Pages 139-152

  Bril, Vera ^a   Allenby, Kent ^b   Midroni, Gyl ^b   O'Connor, Paul W ^b   Vajsar, Jiri ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMIMMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTRAGLOBULIN; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; DEMYELINATING DISEASE; DERMATOMYOSITIS; DRUG EFFICACY; DRUG INDICATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRACTABLE EPILEPSY; INTRAVENOUS DRUG ADMINISTRATION; MYASTHENIA GRAVIS; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; STIFF MAN SYNDROME;

AGED; CHILD; DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROLOGY; POLYRADICULONEUROPATHY;

EID: 0032915041     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Pirofsky B, Kinzey DM. Intravenous immune globulins: a review of their uses in selected immunodeficiency and autoimmune disease. Drugs 1992; 43: 6-14.
2. Infectious Diseases and Immunization Committee, Ottawa, Ontario, Canada. Intravenous immune globulin use in children. Can Med Assoc J 1992; 146: 121-124.
3. Rivet C. Canadian Blood Agency/Agence Canadienne du sang: Utilization management of albumin and intravenous immune globulin. Canadian Apheresis Group Bulletin 1995: 7-8.
4. van der Meché FG, Schmitz PI, for the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
5. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-1136.
6. van der Meché FG. The Guillain-Barré syndrome. In: McLeod JG, ed. Inflammatory Neuropathies. BailliPre's Clin Neurol 1994; 3: 73-94.
7. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996; 46: 100-103.
8. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome Lancet 1997; 349(9047): 225-230.
9. Corbanese U, Martinuzzi A, Possamai C, et al. Guillain-Barré syndrome with associated thrombocytopenia: prompt response to combined corticosteroid and immunoglobulin treatment. Neuromuscul Disord 1998; 8: 50-52.
10. Imai N, Miyata K, Terayama Y, Ishihara N. [A case of Guillain-Barré syndrome treated with plasma exchange and intravenous high-dose immune globulin]. Rinsho Shinkeigaku 1997; 37: 520-522.
11. Enders U, Toyka KV, Hartung HP, Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol 1997; 76: 112-116.
12. Reisin RC, Pociecha J, Rodriguez E, et al. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996 May; 14: 308-312.
13. Shahar E, Shorer Z, Roifman CM, et al. Immune globulins are effective in severe pediatric Guillain-Barré syndrome. Pediatr Neurol 1997; 16: 32-36.
14. Zafeiriou DI, Kontopoulos EE, Katzos GS, Gombakis NP, Kanakoudi FG. Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome. Brain Dev 1997; 19: 323-325.
15. Kanra G, Ozon A, Vajsar J, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Pediatr 1997; 1: 7-12.
16. van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991; 48: 217-220.
17. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind placebo controlled cross-over study. Neurology 1990; 40: 209-212.
18. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-39.
19. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Arm Neurol 1994; 36: 838-845.
20. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controled, cross-over study. Brain 1996; 119(Pt 4): 1067-1077.
21. van Dijk GW, Notermans NC, Franssen H, Oey PL, Wokke JH. Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms. J Neurol 1996; 243: 318-322.
22. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997; 20: 1569-1575.
23. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997; 20: 1008-1015.
24. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain 1996; 119 ( Pt 3): 765-774.
25. Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 1995; 88: 493-502.
26. Grehl H, Jaspert A, Claus D, Neundorfer B. Immunglobulintherapie chronisch-entzundlicher Neuropathien [Immunoglobulin therapy of chronic inflammatory neuropathies]. Nervenarzt 1996; 67: 1003-1010.
27. Mariette X, Chastang C, Clavelou P, et al., for The IgM-associated Polyneuropathy Study Group. A randomized clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997; 63: 28-34.
28. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321-328.
29. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin [see comments]. Ann Neurol 1993; 33: 237-242.
30. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44(3 Pt 1): 429-432.
31. Comi G, Nemni R, Amadio S, Galardi G, Leocani L. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. Mult Scler 1997; 3: 93-97.
32. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998; 153: 203-214.
33. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721-730.
34. Azulay JP, Rihet P, Pouget J, et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997; 62: 391-394.
35. van den Berg LH, Franssen H, Wokke JH. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998; 121( Pt 3): 421-428.
36. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1997; 63: 765-769.
37. Ferrero B, Durelli L, Cavallo R, et al. The mechanism of action of high-dose immunoglobulin G. Ann NY Acad Sci 1993; 681: 563-566.
38. Arsura EL. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989; 53: S170-S179.
39. Edan G, Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994; 57: 55-56.
40. Uchiyama M, Yukinovu I, Takaya N, et al. High-dose gammaglobulin therapy of generalized myasthenia gravis. Ann NY Acad Sci 1987; 505: 868-871.
41. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Arm NY Acad Sci 1987; 505: 472-499.
42. Jonger JL, van Doorn PA, van der Meché FG. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol 1998; 245: 26-31.
43. van der Meché FG, van Doorn PA. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 1997; 20: 136-147.
44. Tatay J, Diez-Tejedor E, Frank A, et al. [Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis]. Rev Neurol 1997; 25: 1402-1406.
45. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-796.
46. Bassan H, Muhlbaur B, Tomer A, Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol 1998; 18: 181-183.
47. Herrmann DN, Carney PR, Wald JJ. Juvenile myasthenia gravis: treatment with immune globulin and thymectomy. Pediatr Neurol 1998; 18: 63-66.
48. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-person syndrome with intravenous immunoglobulin. Neurology 1994; 44: 1652-1654.
49. Karlson EW, Sudarsky L, Ruderman E, et al. Treatment of stiff-person syndrome with intravenous immune globulin. Arthritis Rheum 1994; 37: 915-918.
50. Barker RA, Marsden CD. Successful treatment of stiff-person syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62(letter): 426-427.
51. Lepidi H, Frances V, Figarella-Branger D, et al. Local expression of cytokines in neuropathology. Appl Neurobiol 1998; 24: 73-79.
52. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-86.
53. Heckmatt J, Saunders C, Peters AM, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1(8646): 1063-1066.
54. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol 1991; 54: 1007-1008.
55. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143-1149.
56. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukpaheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380-1384.
57. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16: 1545-1547.
58. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513-515.
59. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-168.
60. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheum 1994; 21: 1092-1097.
61. Barohn RJ. The therapeutic dilemma of inclusion body myositis. Neurology 1997; 48: 567-568.
62. van der Meulen MF, Hoogendijk JE, Jansen GH, Veldman H, Wokke JH. Absence of characteristic features in two patients with inclusion body myositis. J Neurol Neurosurg Psychiatry 1998; 64(3): 396-398.
63. Horvath R, Fu K, Johns T, et al. Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. J Neuropathol Exp Neurol 1998; 57(5): 396-403.
64. Sussman GL, Pruzanski W. The role of intravenous infusions of gamma globulin in the therapy of polymyositis and dermatomyositis. J Rheum 1994; 21: 990-992.
65. Dalakas MC, Illia I, Dambrosia J, et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
66. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-172.
67. Collet E, Dalac S, Maerens B, et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231-234.
68. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases. Arch Dis Child 1995; 72: 25-28.
69. Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1997; 38: 111-115.
70. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-716.
71. Rotherfelder U, Neu I, Pelka R. Therapy for multiple sclerosis with immunoglobulin G. Munch Med Wochenschr 1982; 124: 74-78.
72. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experience with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986; 136: 477-480.
73. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22: 205-212.
74. van Engelen BG, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Arm Neurol 1992; 32: 834-835.
75. Noseworthy JH, Rodriguez M, An KN, et al. IVIG treatment in multiple sclerosis: pilot study results and design of placebo-controlled, double-blind clinical trial. Arm Neurol 1994; A(abstr): 325(P266).
76. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of high-dose intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-1236.
77. Achiron A, Gilad R, Margalit R, et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune diseases: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994; 57(Suppl.): 57-61.
78. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349(9052): 589-593.
79. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult Scler 1997; 3: 137-141.
80. Sorensen PS, Wanscher B, Schreiber K, et al. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler 1997; 3: 145-148.
81. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402.
82. Paty DW, Li DKB, for the UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-Ib is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
83. Achiron A, Barak Y, Goren M, et al. Intravenous immunoglobulin in multiple sclerosis: clinical and neuroradiologic results and implications for possible mechanisms of action. Clin Exp Immunol 1996; 104(Suppl.-1): 67-70.
84. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997; 3: 370-376.
85. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50(5): 12731281.
86. van Engelen BG, Renier WO, Weemaes CM, Gabreels FJ, Meinardi H. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 1994; 19: 181-190.
87. van Engelen BG, Renier WO, Weemaes CM, et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. Eur J Pediatr 1994; 153: 762-769.
88. van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994; 24: 162-166.
89. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients [see comments]. Neurology 1994; 44: 1030-1036.
90. Fayad MN, Choueiri R, Mikati M. Landau-Kleffner syndrome: consistent response to repeated intravenous gamma-globulin doses: a case report. Epilepsia 1997; 38: 489-494.
91. Lagae LG, Silberstein J, Gillis PL, Casaer PJ. Successful use of intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatr Neurol 1998; 18: 165-168.
92. Roifman C (chair), Balter M, Blanchette V, et al., for The Consensus Working Group. Present and future uses of IVIG. McLean Hunter Healthcare (newsletter) 1997.